Deodat Hounga breaks new ground on sickle cell disease care in Benin

Deodat Hounga, a researcher at the LINCS laboratory of the University of Strasbourg, has highlighted disparities in the perception and management of sickle cell disease in Benin, revealing that the disease is endemic and poorly understood, directly impacting patients' quality of life. This thesis, defended in 2025, underscores the urgency of improving care in this context.

Sickle cell disease, the world's leading genetic disorder, affects more than 100 million people. Deodat Hounga's research revealed notable differences in the perception of this disease between France, French Guiana, and Benin. In Benin, the disease is endemic, but patients face obstacles in accessing care, compounded by stigma and a lack of awareness.

The study showed that, although local understanding of sickle cell disease is better in Benin, patients suffer from limited access to care. The findings underscore the importance of adapting awareness strategies and strengthening health infrastructure to meet the specific needs of Beninese patients.

The implications of this research are strategic for decision-makers. It is recommended to invest in awareness campaigns and improved health infrastructure for sickle cell disease in Benin. This represents a significant opportunity for investors, given the prevalence of the disease and the challenges of access to care.

« "The perception of sickle cell disease in Benin is deeply rooted in the local context, but patients face access-to-care challenges that require urgent attention." »

« "Deodat Hounga's study highlights the need for an integrated approach to improving access to care in West Africa, a critical issue for decision-makers and investors." »